Achillion, GCA Therapeutics deal

Achillion granted GCA an exclusive license to develop and commercialize elvucitabine to treat HBV and HIV infection in China, Hong Kong and Taiwan. The L-cytosine nucleoside analog reverse transcriptase inhibitor is in Phase II testing to treat HBV and HIV. Achillion is eligible for undisclosed milestones and double-digit royalties. ...